presence of hACE2. In addition, human AXL or TIM-1 was expressed in some cells. Ad5 virus vectors (MOI=~50) delivered the human genes. N=8-16 (single experiment)

Figure 12

Ability of SARS-CoV-2 to infect HAE cultures in the presence of camostat, bemcentinib or E64. Shown are duplicate cultures from HAEs from 3 different donors.

Figure 13

Representative data from three of the lung tumor lines from John Minna that support SARS-COV-2 infection which is sensitive to both E64 and bemcentinib.

Figure 14

Ability of PS receptor inhibitors to decrease SARS-Cov-2 infection of Huh7 cells.

Figure 15

Polyclonal sera against hACE2 does not inhibit SARS-CoV-2 spike-dependent infection. Antisera concentrations noted above were added ~1 h prior to infection and maintained in the culture for the 24 h infection period.

Figure 16

(A) Vero E6 cell studies where it was observed that bemcentinib was highly effective at inhibiting SARS-CoV-2 spike dependent entry, but tilvestamab had no effect. VSV/SARS-CoV-2 spike pseudovirions were used this experiment.

(B) Tilvestamab has no effect on SARS-CoV-2 infection of CalU3 cells.

Figure 17

MHV present in livers of infected C57BL/6 mice at day 3 of infection. Virus was administered intraperitoneally. Virus was assessed by titering clarified liver homogenates on a murine CEACAM+ cell line (A) or by qRT-PCR (B-C). No statistical significance is achieved when treatments are grouped into n=5.

Figure 18

Virus load at day X of infection with 50,000 iu of MHV. Same data as shown in Fig. 17C. However, untreated and vehicle only groups of mice given 50,000 iu of MHV are now pooled. When compared in a Student’s t test, the bemcentinib group now has a significantly reduced virus load.

Figure 19

Expression changes in interferon related genes at day 3 in spleens of C57BL/6 mice infected with 500 iu of MHV in the presence of vehicle control (LH bar in each pair) or bemcentinib (RH bar in each pair).

Figure 20

CLAIMS

1. Use of an inhibitor of AXL activity or expression (AXLi) in the manufacture of a medicament for treating a virus infection in a subject, preventing or reducing transmission of a virus infection in a subject, or increasing viral clearance from a subject, wherein the medicament is formulated to administer to the subject an effective amount of the AXLi.

2. The use according to claim 1 , wherein the virus infection is:
(i) a coronavirus infection;
(ii) an alphaletovirus infection;
(iii) an orthocoronavirus infection;
(iv) an alphacoronavirus infection;
(v) a betacoronavirus infection;
(vi) a gammacoronavirus infection;
(vii) a deltacoronavirus infection;
(viii) a betacoronavirus, lineage B, infection;
(ix) a SARS-CoV infection;
(x) a betacoronavirus, lineage C, infection; or
(xi) a MERS-CoV infection.

3. The use according to claim 1, wherein the virus infection is a SARS-CoV-2 infection.

4. The use according to claim 3, wherein the SARS-CoV-2 infection is caused by:
(i) a variant comprising a mutation at position E484, optionally wherein the mutation is a E484K substitution;
(ii) a variant comprising a mutation at position N501, optionally wherein the mutation is a N501Y substitution;
(iii) a variant comprising a mutation at position K417, optionally wherein the mutation is a K417N or a K417T substitution;
(iv) a variant comprising a mutation at one or more of the positions L18, L242-244, D80, D215, D614, and A701, optionally wherein the variant comprises a mutation at each of the positions;
(v) a variant comprising one or more of the mutations L18F, ΔL242-244, D80A, D215G, D614G, and A701V, optionally wherein the variant comprises all of the mutations;
(vi) the B.1.351 variant;
(vii) the B.1.1.7 variant;
(viii) the P.1 variant; or
(ix) the B.1.526 variant.

5. The use according to any one of claims 1 to 24, wherein the medicament is formulated to be administered in combination with a second antiviral agent, an anti-inflammatory agent, and / or an immunosuppressive agent.

6. The use according to claim 5, wherein the second antiviral agent is:
(i) selected from the group consisting of: a protease inhibitor, a helicase inhibitor, and a cell entry inhibitor;

(ii) selected from the group consisting of: ribavirin, an interferon, or a combination of both; and / or

(iii) remdesivir.

7. The use according to claim 5, wherein the anti-inflammatory agent is:

(i) a corticosteroid;

(ii) a glucocorticoid steroid; and / or

(iii) dexamethasone.

8. The use according to claim 5, wherein the immunosuppressive agent is an IL-6 anatgonist or is Tocilizumab.

9. The use of any one of claims 1 to 8, wherein the medicament is formulated such that the AXLi and/or second antiviral agent is comprised in a pharmaceutical composition, optionally further comprising a pharmaceutically acceptable excipient, and optionally wherein the medicament is formulated to be administered by inhalation.

10. The use according to any previous claim, wherein the subject:

(i) is human;

(ii) has, is suspected of having, or is at high risk of having a viral infection;

(iii) is a healthcare professional;

(iv) is at risk of severe symptoms if they were to catch the viral infection;

(v) has one or more comorbidity selected from: respiratory system disease, cardiovascular disease, diabetes, hypertension, cancer, or a suppressed immune system;

(vi) has two or more or three or more comorbidities;


(vii) is at least 60 years old, is at least 70 years old, or is at least 80 years old;

(viii) is male; and / or

(ix) is selected for treatment on the basis of having one or more of the features of (ii) to (viii).

11. The use according to any one of claims 1 to 9, wherein the subject's CRP level is at least 30 µg/mL or is at least 50 µg/mL.

12. The use according to any one of claims 1 to 11, wherein the AXLi is a compound of formula (I):



(I)

wherein:

R^1, R^4 and R^5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, aralkyl, $-C(O)R^8$, $-C(O)N(R^6)R^7$, and $-C(=NR^6)N(R^6)R^7$;

R^2 and R^3 are each independently a polycyclic heteroaryl containing more than 14 ring atoms optionally substituted by one or more substituents selected from the group consisting of oxo,

thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, $-R^9-OR^8$, $-R^9-O-R^{10}-OR^8$, $-R^9-O-R^{10}-O-R^{10}-OR^8$, $-R^9-O-R^{10}-CN$, $-R^9-O-R^{10}-C(O)OR^8$, $-R^9-O-R^{10}-C(O)N(R^6)R^7$, $-R^9-O-R^{10}-S(O)_pR^8$ (where p is 0, 1 or 2), $-R^9-O-R^{10}-N(R^6)R^7$, $-R^9-O-R^{10}-C(NR^{11})N(R^{11})H$, $-R^9-OC(O)-R^8$, $-R^9-N(R^6)R^7$, $-R^9-C(O)R^8$, $-R^9-C(O)OR^8$, $-R^9-C(O)N(R^6)R^7$, $-R^9-N(R^6)C(O)OR^8$, $-R^9-N(R^6)C(O)R^8$, $-R^9-N(R^6)S(O)_tR^8$ (where t is 1 or 2), $-R^9-S(O)_tOR^8$ (where t is 1 or 2), $-R^9-S(O)_pR^8$ (where p is 0, 1 or 2), and $-R^9-S(O)_tN(R^6)R^7$ (where t is 1 or 2);

or R^2 is a polycyclic heteroaryl containing more than 14 ring atoms as described above and R^3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, $-R^{13}-OR^{12}$, $-R^{13}-OC(O)-R^{12}$, $-R^{13}-O-R^{14}-N(R^{12})_2$, $-R^{13}-N(R^{12})-R^{14}-N(R^{12})_2$, $-R^{13}-N(R^{12})-R^{14}-N(R^{12})_2$, $-R^{13}-N(R^{12})_2$, $-R^{13}-C(O)R^{12}$, $-R^{13}-C(O)OR^{12}$, $-R^{13}-C(O)N(R^{12})_2$, $-R^{13}-C(O)N(R^{12})-R^{14}-N(R^{12})R^{13}$, $-R^{13}-C(O)N(R^{12})-R^{14}-OR^{12}$, $-R^{13}-N(R^{12})C(O)OR^{12}$, $-R^{13}-N(R^{12})C(O)R^{12}$, $-R^{13}-N(R^{12})S(O)_tR^{12}$ (where t is 1 or 2), $-R^{13}-S(O)_tOR^{12}$ (where t is 1 or 2), $-R^{13}-S(O)_pR^{12}$ (where p is 0, 1 or 2), and $-R^{13}-S(O)_tN(R^{12})_2$ (where t is 1 or 2);

or R^3 is a polycyclic heteroaryl containing more than 14 ring atoms as described above, and R^2 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, $-R^{13}-OR^{12}$, $-R^{13}-OC(O)-R^{12}$, $-R^{13}-O-R^{14}-N(R^{12})_2$, $-R^{13}-N(R^{12})-R^{14}-N(R^{12})_2$, $-R^{13}-N(R^{12})-R^{14}-N(R^{12})_2$, $-R^{13}-N(R^{12})_2$, $-R^{13}-C(O)R^{12}$, $-R^{13}-C(O)OR^{12}$, $-R^{13}-C(O)N(R^{12})_2$, $-R^{13}-C(O)N(R^{12})-R^{14}-N(R^{12})R^{13}$, $-R^{13}-C(O)N(R^{12})-R^{14}-OR^{12}$, $-R^{13}-N(R^{12})C(O)OR^{12}$, $-R^{13}-N(R^{12})C(O)R^{12}$, $-R^{13}-N(R^{12})S(O)_tR^{12}$ (where t is 1 or 2), $-R^{13}-S(O)_tOR^{12}$ (where t is 1 or 2), $-R^{13}-S(O)_pR^{12}$ (where p is 0, 1 or 2), and $-R^{13}-S(O)_tN(R^{12})_2$ (where t is 1 or 2);

each R^6 and R^7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl,

optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, $-R^{10}-OR^8$, $-R^{10}-CN$, $-R^{10}-NO_2$, $-R^{10}-N(R^8)_2$, $-R^{10}-C(O)OR^8$ and $-R^{10}-C(O)N(R^8)_2$, or any R^6 and R^7, together with the common nitrogen to which they are both attached, form an optionally substituted *N*-heteroaryl or an optionally substituted *N*-heterocyclyl;

each R^8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkynyl;

each R^9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain;

each R^{10} is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain;

each R^{11} is independently selected from the group consisting of hydrogen, alkyl, cyano, nitro and $-OR^8$;

each R^{12} is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl , optionally substituted heteroarylalkyl, $-R^{10}-OR^8$, $-R^{10}-CN$, $-R^{10}-NO_2$, $-R^{10}-N(R^8)_2$, $-R^{10}-C(O)OR^8$ and $-R^{10}-C(O)N(R^8)_2$, or two $R^{12's}$, together with the common nitrogen to which they are both attached, form an optionally substituted *N*-heterocyclyl or an optionally substituted *N*-heteroaryl;

each R^{13} is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and

each R^{14} is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain;

as an isolated stereoisomer or mixture thereof or as a tautomer or mixture thereof, or a pharmaceutically acceptable salt or N-oxide thereof.

13. The use according to any one of claims 1 to 11, wherein the AXLi is selected from the group consisting of:

1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;

1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7-(*S*)-pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;

1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7-(*R*)-pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(3-fluoro-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^5-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-1-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^5-(7-(*S*)-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(*t*-butoxycarbonylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(acetamido)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-((2*R*)-2-(methoxycarbonyl)pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(4,4-difluoropiperidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-((methoxycarbonylmethyl)(methyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-((2*R*)-2-(carboxy)pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(4-(ethoxycarbonyl)piperidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(4-(carboxy)piperidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-((carboxymethyl)(methyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(4-(ethoxycarbonylmethyl)piperazin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(4-(carboxymethyl)piperazin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-1-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-amino-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*s*)-7-(di(cyclopropylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;

1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((2-methylpropyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((propyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(dipropylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(diethylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(cyclohexylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(cyclopentylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((1-cyclopentylethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(2-propylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((3,3-dimethylbut-2-yl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((cyclohexylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(di(cyclohexylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((5-chlorothien-2-yl)methyl)amino-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((2-carboxyphenyl)methyl)amino-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((3-bromophenyl)methyl)amino-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(dimethylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(cyclobutylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(3-pentylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((2,2-dimethylpropyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(di(cyclopentylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;

1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((cyclopentylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(di(bicyclo[2.2.1]hept-2-en-5-ylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((bicyclo[2.2.1]hept-2-en-5-ylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(3-methylbutylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(di(3-methylbutyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(2-ethylbutylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(but-2-enylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(butyl(but-2-enyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^5-((7*S*)-7-(*t*-butoxycarbonylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-amino-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(dimethylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(diethylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(dipropylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(di(cyclopropylmethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(di(3-methylbutyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(cyclobutylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(cyclohexylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;

1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-((methylethyl)amino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(cyclopentylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine; and
1-(6,7-dihydro-5*H*-pyrido[2',3':6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7*S*)-7-(2-butylamino)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine;
or pharmaceutically acceptable salts thereof.

14. The use according to any one of claims 1 to 11, wherein the AXLi is:
(i) 1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-((7-(*S*)-pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulene-2-yl)-1*H*-1,2,4-triazole-3,5-diamine, or a pharmaceutically acceptable salt thereof; Or
(ii) bemcentinib.

15. The use according to any one of claims 1 to 11, wherein the AXLi is selected from the group consisting of:
- Dubermatinib (CAS No.1341200-45-0 ; UNII 14D65TV20J);
- Gilteritinib (CAS No. 1254053-43-4 ; UNII 66D92MGC8M);
- Cabozantinib (CAS No. 849217-68-1 ; UNII 1C39JW444G);
- SGI7079 (CAS No. 1239875-86-5);
- Merestinib (CAS No. 1206799-15-6 ; UNII 5OGS5K699E);
- Amuvatinib (CAS No. 850879-09-3 ; UNII SO9S6QZB4R);
- Bosutinib (CAS No. 380843-75-4 ; UNII 5018V4AEZ0);
- Sitravatinib (CAS No. 1123837-84-2 ; UNII CWG62Q1VTB);
- XL092;
- Glesatinib (CAS No. 936694-12-1; UNII 7Q29OXD98N); and
- foretinib (CAS No. 849217-64-7; UNII 81FH7VK1C4).

16. The use according to any one of claims 1 to 11, wherein the AXLi is an antibody.

17. The use according to claim 16 wherein the antibody:
(i) is selected from the group consisting of:
- the 1613F12 antibody disclosed in WO/2013/064685;
- the 110D7 antibody disclosed in WO/2014/068139;
- the 1003A2 antibody disclosed in WO/2014/068139;
- the 1024G11 antibody disclosed in WO/2014/068139;
- the hu10G5 antibody disclosed in WO/2017/220695; and
- the YW327.6S2 antibody disclosed in WO/2011/159980;

(ii) comprises the 6 CDRs having the sequences of SEQ ID Nos. 1 to 6;
(iii) comprises the 6 CDRs having the sequences of SEQ ID Nos. 7 to 12;
(iv) comprises:
- a VH domain having the sequence of SEQ ID No. 13 and a VL domain having the sequence of SEQ ID NO.15;

- a VH domain having the sequence of SEQ ID No. 13 and a VL domain having the sequence of SEQ ID NO.16;
- a VH domain having the sequence of SEQ ID No. 14 and a VL domain having the sequence of SEQ ID NO.15; or
- a VH domain having the sequence of SEQ ID No. 14 and a VL domain having the sequence of SEQ ID NO.16;

(v) comprises all 6 of the CDRs comprised in:

- a VH domain having the sequence of SEQ ID No. 13 and a VL domain having the sequence of SEQ ID NO.15;
- a VH domain having the sequence of SEQ ID No. 13 and a VL domain having the sequence of SEQ ID NO.16;
- a VH domain having the sequence of SEQ ID No. 14 and a VL domain having the sequence of SEQ ID NO.15; or
- a VH domain having the sequence of SEQ ID No. 14 and a VL domain having the sequence of SEQ ID NO.16;

18. The use according to claim 16, wherein the antibody is Tilvestamab,

19. A pharmaceutical compostion comprising an AXLi as defined in any one of claims 12 to 18 and a second anti-viral agent.

20. The pharmaceutical compostion of claim 19, wherein the second anti-viral agent is as defined in any one of claims 5 to 8.